BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

...the flood of new studies is outpacing peer review, he said. Rhonda Rhyne, CEO of cardiovascular diagnostics...
BioCentury | Jun 16, 2018
Finance

Rejuvenating aging

Anti-aging company Juvenescence Ltd. is hoping to bring a total of 10 candidates from its portfolio companies and academic partnerships into the clinic over the next two years with its recent $50 million series A...
BioCentury | Oct 10, 2016
Financial News

Genfit completes private placement

Genfit S.A. (Euronext:GNFT), Loos, France Business: Endocrine/Metabolic, Cardiovascular, Diagnostic Date completed: 2016-10-06 Type: Private placement Raised: EUR33.9 million ($38.1 million) Shares: 1.7 million Price: EUR20 Shares after offering: 28 million Investor: Institutional investors Note: The...
BioCentury | Jul 6, 2016
Financial News

BioGeneration raises EUR 25 million for third fund

BioGeneration Ventures announced a EUR 25 million ($27.8 million) first close for the firm's third life sciences fund. BioGeneration Capital Fund III is targeting a final close of EUR 50 million ($55.6 million). LPs include...
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | May 19, 2016
Strategy

Mind the gap

A wave of initiatives and funds in the U.K. over the last two years has been flooding the gap between the country's prolific scientific achievements and its comparatively low rate of commercialization. The hope is...
BioCentury | May 12, 2016
Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
BioCentury | Apr 21, 2016
Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

Last month's opening by Johnson & Johnson of the Houston-based JLABS incubator is being seen as a coup by local leaders hoping to make the city the "third coast" of biotech. But stakeholders inside and...
BioCentury | Apr 13, 2016
Company News

Management tracks

Women's health and hematology play AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) hired Edward Myles as SVP and CFO. Myles was CFO and COO at Ocata Therapeutics Inc. , which Astellas Pharma Inc. (Tokyo:4503) acquired. Metabolic and cardiovascular company...
Items per page:
1 - 10 of 1152
BioCentury | Jun 23, 2020
Tools & Techniques

AI tools against COVID-19: a view from where the rubber hits the road

...the flood of new studies is outpacing peer review, he said. Rhonda Rhyne, CEO of cardiovascular diagnostics...
BioCentury | Jun 16, 2018
Finance

Rejuvenating aging

Anti-aging company Juvenescence Ltd. is hoping to bring a total of 10 candidates from its portfolio companies and academic partnerships into the clinic over the next two years with its recent $50 million series A...
BioCentury | Oct 10, 2016
Financial News

Genfit completes private placement

Genfit S.A. (Euronext:GNFT), Loos, France Business: Endocrine/Metabolic, Cardiovascular, Diagnostic Date completed: 2016-10-06 Type: Private placement Raised: EUR33.9 million ($38.1 million) Shares: 1.7 million Price: EUR20 Shares after offering: 28 million Investor: Institutional investors Note: The...
BioCentury | Jul 6, 2016
Financial News

BioGeneration raises EUR 25 million for third fund

BioGeneration Ventures announced a EUR 25 million ($27.8 million) first close for the firm's third life sciences fund. BioGeneration Capital Fund III is targeting a final close of EUR 50 million ($55.6 million). LPs include...
BioCentury | Jun 9, 2016
Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | May 19, 2016
Strategy

Mind the gap

A wave of initiatives and funds in the U.K. over the last two years has been flooding the gap between the country's prolific scientific achievements and its comparatively low rate of commercialization. The hope is...
BioCentury | May 12, 2016
Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
BioCentury | Apr 21, 2016
Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

Last month's opening by Johnson & Johnson of the Houston-based JLABS incubator is being seen as a coup by local leaders hoping to make the city the "third coast" of biotech. But stakeholders inside and...
BioCentury | Apr 13, 2016
Company News

Management tracks

Women's health and hematology play AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) hired Edward Myles as SVP and CFO. Myles was CFO and COO at Ocata Therapeutics Inc. , which Astellas Pharma Inc. (Tokyo:4503) acquired. Metabolic and cardiovascular company...
Items per page:
1 - 10 of 1152